---
created: 2025-04-13
updated: 2025-04-13T10:52
id: Qa[I;&jsxj
specialty: pharmaco
specialty_id: 89
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::18-pulm::01-intro::05-pulm-circulation
  - "source/ak-step1-v11:": 
  - theme/firstaid::05-pharmacology::02-autonomic-drugs::15-phosphodiesterase-inhibitors::et1-antagonist
  - "source/ak-step1-v11:": 
  - theme/firstaid::16-respiratory::05-pharm::06-pulmonary-hypertension-drugs
  - "source/ak-step1-v11:": 
  - theme/firstaid::16-respiratory::05-pharm::06-pulmonary-hypertension-drugs::bosentan
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::04-general-physiology::14-smooth-muscle
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::08-respiratory::05-pulmonary-htn-drugs
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::19-respiratory::endothelin-receptor-antagonists-(bosentan)
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::04-smooth-muscle::fa-pulm
  - "source/ak-step1-v11:": 
  - theme/uworld::100-999::900-999::903
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::14000-14999::14847
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::14000-14999::14959
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield
  - source/ak-step1-v11::^systems::respiratory::pharmacology
  - "source/ak-step2-v11:": 
  - theme/b&b::07-pulmonary::03-other-topics::01-pulmonary-hypertension"
type: flashcard
---

# Question
**Bosentan, ambrisentan** are competitive **endothelin-1 receptor** **antagonists** that lower pulmonary arterial pressure and improve the exertional dyspnea in patients with **pulmonary arterial hypertension**

---

# Answer
"""NO PROS, only decreases"" = NO and prostacyclin = vasodilators == decrease proliferation; both are decreased in PAH   endothelin-1 = vasoconstriction & increased proliferation of smooth muscle; together w/ thromboxane A2, the only ones INCREASED in PAH"